Details for Patent: 11,679,119
✉ Email this page to a colleague
Which drugs does patent 11,679,119 protect, and when does it expire?
Patent 11,679,119 protects BORTEZOMIB and is included in one NDA.
This patent has one patent family member in one country.
Drugs Protected by US Patent 11,679,119
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-001 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA | ⤷ Subscribe | ||||
| Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-001 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA | ⤷ Subscribe | ||||
| Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-002 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA | ⤷ Subscribe | ||||
| Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-002 | Jul 27, 2022 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,679,119
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2023049346 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
